
OYE Therapeutics Secures $5.475 Million Series A Funding for Caffeine-Based Anesthesia Recovery and Overdose Reversal Therapy
OYE Therapeutics has raised $5.475 million in Series A financing to advance clinical development of its high-concentration intravenous caffeine therapy for anesthesia recovery and opioid overdose reversal, with Phase 1 trials planned for early 2026.
Read full story























